Camurus

Camurus P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Camurus (CAMX.ST) as of Oct 27, 2026 is 32.16. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 72.05 — a change of -55.37% (lower).

P/CF

32.16

YoY

-55.37%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Camurus is 2025 32.16 . P/CF (Price-to-Cash-Flow Ratio) of Camurus was 2024 72.05 . It decreases by -55.37% lower compared to the previous year.

The Camurus P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-101.99 SEK
Jan 1, 2019
-69.13 SEK
Jan 1, 2020
-117.04 SEK
Jan 1, 2021
-194.90 SEK
Jan 1, 2022
276.22 SEK
Jan 1, 2023
46.06 SEK
Jan 1, 2024
72.05 SEK
Jan 1, 2025
32.16 SEK
The Camurus P/CF history
YEARP/CFYoY
32.16-55.37%
72.05+56.42%
46.06-83.32%
276.22-241.73%
-194.90+66.52%
-117.04+69.31%
-69.13-32.22%
-101.99-25.91%
-137.66+2.32%
-134.53-97.28%
-4,941.41-1,327.31%
402.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Camurus Stock analysis

What does Camurus do? Camurus AB is a Swedish biopharmaceutical company that specializes in the development of innovative medications for the treatment of serious diseases. The company was founded in 1991 by an interdisciplinary team of chemists, biologists, and drug developers and is headquartered in Lund, Sweden. Camurus AB specializes in the development of medications based on long-acting drug release technology. This technology allows medications to be administered in a very precise manner and over a longer period of time. This enables the benefits of a constant drug concentration in the blood to be utilized without requiring multiple doses per day. The core business of Camurus AB includes the development of medications for the treatment of pain, cancer, and addiction. The company works closely with clients, partners, and academic institutions to bring innovative medications to market that can have a significant impact on patients' lives. One of Camurus AB's key areas is pain therapy. The company has developed a novel technology that allows pain medications to be administered in the form of sprays and patches. This technology is based on the release of buprenorphine, a potent painkiller that previously could only be administered as repeated single doses or in the form of an implant due to its short half-life. The extended release allows for a sustained high concentration of the drug in the blood, without the need for the patient to take multiple single doses. Camurus AB is also active in oncology and has developed medications for the treatment of breast and prostate cancer that also utilize long-acting drug release. These medications help patients better tolerate the side effects of chemotherapy and improve their quality of life. Another important area for Camurus AB is addiction therapy. The company has developed a medication based on buprenorphine for the treatment of opioid dependence. This medication activates the body's own opioid receptors and reduces the cravings for further drugs. In recent years, Camurus AB has introduced several important products to the market and holds a wide portfolio of patents and protective rights. The company is committed to improving patient care and making global healthcare a better and more effective system. In conclusion, Camurus AB is an innovative biopharmaceutical company specializing in the development of medications for the treatment of pain, cancer, and addiction. The company is dedicated to improving global healthcare and works closely with clients, partners, and academic institutions to develop innovative, effective, and patient-oriented solutions. Camurus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Camurus stock

P/CF (Price-to-Cash-Flow Ratio) of Camurus is 32.16 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Camurus changed from 72.05 to 32.16, representing a -55.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Camurus since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Camurus with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Camurus

All Key Metrics — Camurus